Warning letters, 483s, Recalls, Import Alerts, Audit observations
The USFDA has placed Dabur’s Dadra and Nager Haveli facility under Import Alert 66-40 in
FDA has published the USFDA Form 483 issued to sterile drug manufacturing facility of Fareva
USFDA 483 issued to Glenmark Pharma’s Pithampur facility (FEI: 3008565058) in India flagged critical deviations
The U.S. Food and Drug Administration (FDA) issued a Warning Letter to Aspen Biopharma Labs
Piramal Pharma’s API unit at Navi Mumbai (FEI 3008763768) was issued USFDA Form 483 with
Granules India received a warning letter from the USFDA in February 2025. This was along
FDA issued Warning letter to two Chinese API manufacturers following for cGMP violations including failing
Authored by: Venkiteswaran.T.K, Subrangshu Chourdhary, Srinivas Churya Jubilant Generics Roorkee facility was inspected in January
USFDA had inspected the Jiangsu Hengrui Pharma’s Huanghe road site in January 2024. The site
Torrent’s Chhatral, Gujarat facility (FEI: 3012740315) was inspected by USFDA (Investigator Yvins Dezan) in Dec
